NASDAQ:THTX Theratechnologies (THTX) Stock Price, News & Analysis $2.77 -0.15 (-5.14%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$2.75 -0.02 (-0.72%) As of 05/2/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Theratechnologies Stock (NASDAQ:THTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Theratechnologies alerts:Sign Up Key Stats Today's Range$2.75▼$2.9550-Day Range$1.33▼$2.9252-Week Range$1.08▼$3.13Volume429,229 shsAverage Volume796,173 shsMarket Capitalization$127.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company OverviewTheratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.Read More… Receive THTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theratechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address THTX Stock News HeadlinesTheratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIVMay 2 at 7:30 AM | globenewswire.comTheratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 OfferApril 18, 2025 | seekingalpha.comThe Man I Turn to In Times Like ThisA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.May 3, 2025 | Stansberry Research (Ad)Is Theratechnologies Inc. (THTX) the Best Rising Penny Stock to Buy According to Analysts?April 18, 2025 | msn.comTheratechnologies to further evaluate potential sale of the companyApril 16, 2025 | markets.businessinsider.comTheratechnologies Provides Update on Sale ProcessApril 15, 2025 | financialpost.comTheratechnologies Provides Update on Sale ProcessApril 15, 2025 | globenewswire.comTheratechnologies Engages in Exclusive Acquisition TalksApril 15, 2025 | tipranks.comSee More Headlines THTX Stock Analysis - Frequently Asked Questions How have THTX shares performed this year? Theratechnologies' stock was trading at $1.81 at the start of the year. Since then, THTX stock has increased by 53.0% and is now trading at $2.77. View the best growth stocks for 2025 here. How were Theratechnologies' earnings last quarter? Theratechnologies Inc. (NASDAQ:THTX) announced its quarterly earnings results on Thursday, October, 10th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.03 by $0.03. The company earned $22.60 million during the quarter. Read the conference call transcript. When did Theratechnologies' stock split? Theratechnologies shares reverse split before market open on Monday, July 31st 2023. The 1-4 reverse split was announced on Monday, July 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. Does Theratechnologies have any subsidiaries? Theratechnologies subsidiaries include these companies: Katana, Pharma-G Inc., Theratechnologies Europe Inc., Theratechnologies Europe Limited, Theratechnologies Intercontinental Inc., and Theratechnologies U.S. Inc. Who are Theratechnologies' major shareholders? Top institutional shareholders of Theratechnologies include Cyndeo Wealth Partners LLC (0.06%). How do I buy shares of Theratechnologies? Shares of THTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Theratechnologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Theratechnologies investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), CymaBay Therapeutics (CBAY), Novo Nordisk A/S (NVO), Adobe (ADBE) and Celestica (CLS). Company Calendar Last Earnings10/10/2024Today5/02/2025Next Earnings (Estimated)7/09/2025Fiscal Year End11/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:THTX CIK1512717 Webwww.theratech.com Phone(514) 336-7800Fax514-331-9691Employees140Year Founded1993Profitability EPS (Most Recent Fiscal Year)($0.08) Trailing P/E RatioN/A Forward P/E Ratio277.00 P/E GrowthN/ANet Income$-23,960,000.00 Net Margins-3.75% Pretax MarginN/A Return on EquityN/A Return on Assets-4.31% Debt Debt-to-Equity RatioN/A Current Ratio1.08 Quick Ratio0.97 Sales & Book Value Annual Sales$88.67 million Price / Sales1.44 Cash FlowN/A Price / Cash FlowN/A Book Value($0.45) per share Price / Book-6.16Miscellaneous Outstanding Shares45,980,000Free FloatN/AMarket Cap$127.36 million OptionableOptionable Beta1.11 Social Links Free Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:THTX) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theratechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theratechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.